ProQR Therapeutics N.V. (PRQR) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the ProQR Investor Call. Today's conference call is being recorded. At this time, I'd like to turn the call over to Sarah Kiley, Vice President of Investor Relations and Corporate Affairs. Please go ahead. Thank you, and good day, everyone. We appreciate you joining our event today. Today we are pleased to highlight new preclinical proof of concept data for our AX081 and 0810 program targeting NTCP, which was presented yesterday at the ASGCT annual meeting in Baltimore. On slide two, you'll find the agenda for our call and our speakers. From the management team are Daniel DeBoer, our founder and CEO, who will provide a brief introduction, and then Sarah Plattenberg, our Chief Scientific Officer, who will take us through the data presented at ASGCT. Following the presentation, we will have a Q&A session with covering analysts before we conclude the call. Today's event is being recorded and we will have the replay available on our website following the event. You can also find our ASGCT poster under the publications and presentation section of our website. On slide three is our forward-looking statements. During the call today, we will make forward-looking statements There are risks and uncertainties associated with an investment in ProQR, which are described in detail in our SEC filings. I will now turn the call over to Daniel. Daniel? Thank you, Sarah, and good morning and good afternoon, everyone. Thank you for joining us today. We are pleased to share an update with you on the data that we shared at the ASTTC annual meeting. But first, I'll provide a brief overview of the company's strategy and our proprietary Axiomar RNA editing platform. Axiomer was invented at the Procure Labs in 2014 and uses the well-proven modality of oligonucleot...